← 返回

肿瘤微环境来源的 R-spondins 增强抗肿瘤免疫以抑制肿瘤生长并增敏免疫检查点阻断治疗

英文原题:Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy.

查看英文原题

Tumor Microenvironment-Derived R-spondins Enhance Antitumor Immunity to Suppress Tumor Growth and Sensitize for Immune Checkpoint Blockade Therapy.

PubMed 2021/12/01(内容时间) Cancer Discov Q1 · IF 29.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

自然杀伤(NK)细胞和 T 细胞是抗肿瘤免疫反应的关键效应细胞,也是免疫检查点抑制剂的主要靶点。在多种癌症中,我们发现 Wnt 信号增强因子 R-spondin 基因(如 RSPO3)表达与良好预后相关,并与 NK 细胞和 T 细胞基因特征均呈正相关。内皮细胞和癌症相关成纤维细胞是 R-spondin 3 的产生细胞,而 NK 细胞和 T 细胞则分别在肿瘤微环境(TME)中表达 R-spondin 3 受体 LGR6。在肿瘤中外源表达或瘤内注射 R-spondin 3,可增强细胞毒性效应细胞浸润和功能,从而导致肿瘤消退。NK 细胞和 CD8⁺ T 细胞各自并协同参与 R-spondin 3 对不同肿瘤类型的控制。R-spondin 3 的作用部分通过上调 MYC 和核糖体生成介导。重要的是,R-spondin 3 表达增强了肿瘤对抗 PD-1 治疗的敏感性,提示新的治疗途径。意义:本研究识别出增强抗肿瘤免疫及提高免疫检查点阻断敏感性的全新靶点,为开发癌症新型免疫疗法提供依据;同时揭示 Wnt 信号调节 TME 抗癌免疫的机制,并提示 R-spondin-LGR6 轴可能调控 NK 细胞生物学。

展开英文摘要原文

UNLABELLED: Natural killer (NK) cells and T cells are key effectors of antitumor immune responses and major targets of checkpoint inhibitors. In multiple cancer types, we find that the expression of Wnt signaling potentiator R-spondin genes (e. g. , RSPO3) is associated with favorable prognosis and positively correlates with gene signatures of both NK cells and T cells. Although endothelial cells and cancer-associated fibroblasts comprise the R-spondin 3-producing cells, NK cells and T cells correspondingly express the R-spondin 3 receptor LGR6 within the tumor microenvironment (TME).

Exogenous expression or intratumor injection of R-spondin 3 in tumors enhanced the infiltration and function of cytotoxic effector cells, which led to tumor regression. NK cells and CD8+ T cells independently and cooperatively contributed to R-spondin 3-induced control of distinct tumor types. The effect of R-spondin 3 was mediated in part through upregulation of MYC and ribosomal biogenesis.

Importantly, R-spondin 3 expression enhanced tumor sensitivity to anti-PD-1 therapy, thereby highlighting new therapeutic avenues. SIGNIFICANCE: Our study identifies novel targets in enhancing antitumor immunity and sensitizing immune checkpoint inhibition, which provides a rationale for developing new immunotherapies against cancers.

It also offers mechanistic insights on Wnt signaling-mediated modulation of anticancer immunity in the TME and implications for a putative R-spondin-LGR6 axis in regulating NK-cell biology. This article is highlighted in the In This Issue feature, p. 2945.

论文信息

作者
Tang Y、Xu Q、Hu L、Yan X、Feng X、Yokota A、Wang W、Zhan D
单位
Divisions of Pathology and Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio.
文献类型
美国 NIH 资助研究 · 非美国政府资助研究
期刊
Cancer discovery2021 Dec 1
原文标识
PubMed 34193438 · DOI 10.1158/2159-8290.CD-20-0833